Pharmaceutical manufacturer, Linnea SA, has been granted a licence for the production of high-THC medicinal cannabis products in Switzerland.
Linnea SA was granted a narcotics licence by Swissmedic at the end of 2022, making it one of the first companies in Switzerland to be able to produce and export high-THC products.
The company, which has over 40 years experience in the pharmaceutical industry, will begin producing GMP-certified high-THC active pharmaceutical ingredients (APIs) in 2023.
Linnea has been providing gold-standard botanical ingredients for use in the pharmaceutical, cosmetics and dietary supplement industries for over 40 years.
At the forefront of the licensing is Linnea Cannabinoids, a project of Linnea SA. Linnea Cannabinoids aims to manufacture the highest-quality pharmaceutical cannabinoid ingredients and drive research and innovation within the global industry.
Gaining a narcotics licence will allow Linnea to export their standardised and innovative high-THC APIs anywhere in the world where the importation of these products is legal.
Read more: Switzerland’s ‘Weed Care’ trial of adult-use cannabis to launch January 2023
With the demand for GMP certified pharmaceutical-grade cannabis higher than ever, with this licence, Linnea hopes to be able to meet the needs of customers and patients worldwide.
“We are so honoured to be granted a narcotics licence in Switzerland, this opens up many new commercial possibilities for Linnea Cannabinoids and our customers,” commented Susanne Caspar, CEO of Linnea SA.
“High-quality cannabinoid ingredients are essential to producing the pharmaceutical products that patients need, and we are eager to contribute our expertise to this effort. We look forward to the opportunities this will afford us in creating new partnerships and continuing to innovate in the industry.”
You can find Linnea online here and contact them here.
The post Linnea SA to produce medicinal cannabis in Switzerland appeared first on Cannabis Health News.
